Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
Syros Pharmaceuticals has reported Q3 earnings per share at $-1.43, which has decreased by 10.0% compared to Q2, which was -1.3. BioNTech's earnings per share for Q3 sits at $0.73, whereas in Q2, they were at -0.86. Cross Country Healthcare's earnings per share for Q3 sits at $0.39, whereas in Q2, they were at 0.69. Solid Biosciences has reported Q3 earnings per share at $-1.05, which has increased by 16.0% compared to Q2, which was -1.25. Panbela Therapeutics's earnings per share for Q3 sits at $-2.42, whereas in Q2, they were at -7.95.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.